Enorama Pharma

Enorama Pharma is a Swedish pharmaceutical company focused on developing, manufacturing, and commercializing oral nicotine products. Its business centers on tobacco-free white nicotine pouches and nicotine replacement therapy products, sold under the NIC-S® brand and through private-label arrangements, with operations anchored in Sweden and a wholly owned U.S. subsidiary in Florida.

— Enorama Pharma
%
Tobacco-free white nicotine pouches70% Oral nicotine pouch products sold under NIC-S® and private-label formats.
Licensing and other product-related income10% License fees and related income tied to product commercialization and agreements.
Nicotine replacement therapy (NRT)15% Medical nicotine gum and related cessation products.
Product development and formulation services5% Development work, formulations, and commercialization support for nicotine products.

Enorama sells primarily B2B to distributors, retail partners, and brand owners that want oral nicotine products under...

  • U.S. distributors and retail channel partnersprimary

    They buy nicotine pouches for resale in the U.S. market and matter because U.S. commercialization is the strategic priority.

  • Private-label brand ownersprimary

    They source nicotine pouch products under their own branding, using Enorama's formulation and manufacturing platform.

  • NIC-S® consumers through channel partnerssecondary

    End demand for the company's own brand, typically accessed through distributors and retail partners.

  • NRT channel buyerssecondary

    They purchase nicotine gum and related cessation products for regulated pharmacy or consumer health channels.

  • Licensing and collaboration partnersemerging

    They pay for access to formulations, product rights, or commercialization arrangements.

Enorama is headquartered in Sweden, with product development activity tied to Malmö and a smaller office in Stockholm...

  • •Headquartered in Sweden, with offices in Stockholm and Malmö
  • •Product development laboratory located in Malmö
  • •Wholly owned subsidiary in Florida, USA
  • •U.S. is the key commercialization market for nicotine pouches
  • •International sales depend on regulatory and distributor access

Enorama's strategy is to concentrate on tobacco-free white nicotine pouches, with NIC-S® as the core brand and...

01
U.S. market access and commercializationshort-term

The U.S. is the most important market for nicotine pouches, so regulatory clearance and distribution access drive scale.

02
Grow NIC-S® and private-label pouch salesmedium-term

A proprietary brand and private-label model create two commercialization paths and reduce dependence on a single route to market.

03
Broaden product and partnership platformmedium-term

Partnerships and formulation development support market entry, manufacturing scale, and customer-specific offerings.

The main company-specific risk is regulatory dependence in the U.S., where nicotine pouch sales rely on PMTA-related...

critical

PMTA and FDA regulatory risk

U.S. nicotine pouch sales depend on regulatory acceptance and continued compliance with FDA requirements.

Scope
U.S. nicotine pouch business
Materiality
high
high

Financing and liquidity dependence

The company has relied on shareholder and related-party funding to support operations and product development.

Scope
Corporate funding and subsidiary support
Materiality
high
high

Customer and channel concentration

Commercialization depends on a limited number of distributors, retail partners, and private-label relationships.

Scope
NIC-S® and private-label sales
Materiality
medium
medium

Supply-chain and manufacturing execution

The business relies on external partners and a flexible production network to deliver products consistently.

Scope
Product manufacturing and fulfillment
Materiality
medium
medium

Regulatory and competitive market risk

Nicotine products face changing rules, marketing constraints, and strong competition from established players.

Scope
Global oral nicotine market
Materiality
medium
Revenue recognition for product, private-label, and license income
Affects quarterly comparability and reported top-line mix
Capitalized development and intangible asset impairment
Can materially change asset values and amortization expense
Related-party transactions and owner financing
Affects financing costs, disclosures, and governance scrutiny
Intercompany loans and foreign exchange
Can affect financial income/expense and balance-sheet carrying values
Deferred tax assets on loss carryforwards
Can materially affect equity and tax expense

Entera Bio Ltd.

ENTX · Biological Products, (No Diagnostic Substances)

Innoviva, Inc.

INVA · Pharmaceutical Preparations

ALNYLAM PHARMACEUTICALS, INC.

ALNY · Pharmaceutical Preparations

Emmaus Life Sciences, Inc.

EMMA · Pharmaceutical Preparations

Iterum Therapeutics plc

ITRMF · Pharmaceutical Preparations

enGene Therapeutics Inc.

ENGN · Biological Products, (No Diagnostic Substances)

: 11/08/2026